ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
종목 코드 NDRA
회사 이름ENDRA Life Sciences Inc
상장일Jun 28, 2017
CEOMr. Alexander Y. Tokman
직원 수21
유형Ordinary Share
회계 연도 종료Jun 28
주소3600 Green Ct Ste 350
도시ANN ARBOR
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호48105-2440
전화17343350468
웹사이트https://www.endrainc.com/
종목 코드 NDRA
상장일Jun 28, 2017
CEOMr. Alexander Y. Tokman
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음